Drug discovery · Functional genomics

Algen Biotechnologies

A CRISPR and machine learning platform for choosing drug targets, spun out of Jennifer Doudna’s Berkeley lab in 2018. In October 2025 AstraZeneca agreed to pay up to $555 million for the immunology targets it finds.

A Monday in October

On Monday, October 6, 2025, in the week the year’s Nobel Prizes were being announced, a small San Francisco company said it had licensed the output of its software to one of the largest drug makers in the world.

The Financial Times had it first, Reuters followed. AstraZeneca would take exclusive rights to any approved therapy for immune system disorders out of the partnership. Algen Biotechnologies would take an upfront payment, near term payments and milestones worth up to $555 million.

One line in the Reuters story mattered as much as the headline number. “Monday’s deal, however, does not include AstraZeneca buying a stake in the company,” the wire reported, citing an interview with chief executive Chun-Hao Huang. No equity moved. The company had raised $11 million in its first seven years and was, Huang said, “well capitalized.”

The problem it is aimed at

Drug discovery fails in a particular place. Algen’s own 2021 grant application to the National Institutes of Health put a number on it: “Drug discovery is a laborious, time-consuming, and expensive undertaking for biopharma.” Oncology is the worst of it, the application went on, “difficult with new drugs in clinical trials having just 3.4% probability of success.”

Much of that failure is locked in before a trial, at the moment somebody picks a target. Sequencing can say which genes move as a disease progresses. It is far harder to say which are driving it and which are only reacting.

Algen’s answer is to stop reading and start pushing. Its CRISPR system turns individual genes up or down inside human cells, then reads out what happened to hundreds of thousands of single cells at once. A model trained on those perturbations scores each gene by how far it moves a cell away from the diseased state, or toward toxicity. Christine Du, the co-founder who runs the business side, put the aim to Longevity.Technology in 2025: “By capturing billions of dynamic RNA changes and linking them to functional outcomes, we can identify genes that are not just associated with disease, but truly drive it.”

A postdoc and an operator

Chun-Hao Huang took his PhD in Scott Lowe’s lab at Memorial Sloan Kettering and Weill Cornell, then moved to Berkeley as a postdoc with Doudna. He is a co-author with her on a 2018 Trends in Cancer review and on a 2019 Cell paper about p53 and the mevalonate pathway, both still listed on the company news page. Algen says he has “authored over 10 patents filed or issued, 40 scientific papers, and 4,000 citations across top-tier journals.” Du trained as a scientist and took an MBA at Wharton. Jeff Whitten, four decades in industry by way of Turning Point Therapeutics, CalciMedica and Neurocrine, is chief scientific officer.

Doudna is a founding scientific advisor, not an employee, a distinction BioSpace and The Chemical Engineer both drew when the deal landed. The founding story itself is where the record and the company drift apart. Berkeley’s technology transfer office lists the company founders as “Spencer Knight (UC Berkeley Ph.D., 2017, Chemistry and Chemical Biology), Chun-Hao Huang (AACR Research Fellow at UC Berkeley), and Christine Du”. Algen’s own releases name two. Knight appears on the company website as a technical advisor, now a vice president at General Atlantic.

What the platform claims

The fullest public description is a March 2024 Biopharma Dealmakers feature published by Nature Portfolio. AlgenCRISPR is an engineered system with the endonuclease activity removed, so it tunes expression without cutting DNA. AlgenBrain is the deep learning layer trained on the resulting single cell data. The feature says AlgenCRISPR, “in head-to-head comparisons far outperforms other CRISPR-based gene-expression-modulation approaches, delivering up to 99% inhibition or a 2,000-fold increase in expression levels of target genes.” In one program, it says, the model surfaced PARP1, the target of an approved cancer drug, and ranked nine further genes above it.

These are the company’s own figures. The article carries Algen’s byline rather than a reporter’s, and no peer-reviewed paper with an Algen Biotechnologies affiliation appears in PubMed. Searches for AlgenBrain and AlgenCRISPR return nothing there at all.

Six programs, then two

That same 2024 feature described six development programs, three in oncology and three in immunology and metabolic disorders, “with a lead anticancer agent being prepared for clinical trials.”

Eighteen months later the visible pipeline was smaller. Covering the AstraZeneca deal, BiopharmaTrend recorded that Algen’s pipeline then listed “precision oncology programs AB-1 and AB-2 for advanced solid tumors (preclinical), and two immunology programs at discovery stage.” The company website still shows that shape, and there is no Algen study on ClinicalTrials.gov.

What is proven, and what is still claimed

Read plainly: the partnership is real and is corroborated in a counterparty’s annual report, firmer proof than most private biotech announcements ever get. Everything underneath it rests on the company’s own account. Eight years in, the external scoreboard reads one federal grant, no trials, no papers and no securities filings.

What to watch

• A Form D, or a named financing. Nothing has been filed with the SEC since the company was founded in 2018.
• The first registered trial for AB-1 or AB-2. A lead agent was called trial ready in March 2024.
• A peer-reviewed benchmark of AlgenCRISPR against existing CRISPR interference and activation systems.
• Whether AstraZeneca attaches a target, a milestone or a candidate to the collaboration in a future report.
• The other target discovery partnerships described in 2024, one in immunology and one in cardiovascular and metabolic disease, which have never been named.

In their words

Algen Biotechnologies funding profile on HVCFHealthcare Venture Capital Fund

Related companies

• General Proximity: Also in Drug Discovery and Delivery. A San Francisco biotech built on one idea: most disease driving proteins can be controlled, not just blocked, given the right partner protein
• Sixfold Bioscience: Also in Drug Discovery and Delivery. A London company that set out to deliver RNA drugs everywhere except the liver
• CellChorus: Also in Drug Discovery and Delivery. A University of Houston spinout that films immune cells one at a time and scores how well each one kills
• Biocartesian: Also in Drug Discovery and Delivery. A two person, YC-backed lab service that turns tissue and cell samples into what it calls digital molecular maps

Sources

1. Public recordAstraZeneca PLC Form 20-F for fiscal 2025, Exhibit 15.1SEC EDGAR · Feb 24, 2026
2. Public recordEDGAR company name search for ALGENSEC · Sep 22, 2026
3. Public recordNIH RePORTER award 1R41GM146327-01NIGMS · FY2021
4. Public recordClinicalTrials.gov and PubMed queries for Algen, AlgenBrain and AlgenCRISPR, zero recordsNLM · Sep 22, 2026
5. Public recordUC Berkeley IPIRA company page, founders, inventors and founding dateUC Berkeley
6. IndependentAstraZeneca signs up to $555 million AI deal with Algen to develop therapiesReuters · Oct 6, 2025
7. IndependentAstraZeneca, Algen Biotechnologies pen $555M AI pact for immunology targetsFierce Biotech, Ben Adams · Oct 6, 2025
8. IndependentAstraZeneca Makes Another AI Deal With $555M Algen AllianceBioSpace, Tristan Manalac · Oct 6, 2025
9. IndependentAstraZeneca Signs $555 Million AI Deal For CRISPR TherapiesBiopharmaTrend, Roman Kasianov · Oct 6, 2025
10. IndependentAstraZeneca strikes US$555m deal to commercialise AI-discovered immunology drugsThe Chemical Engineer, Sam Baker · Oct 8, 2025
11. IndependentAI-powered gene editing startup lands $555m AstraZeneca dealLongevity.Technology, Danny Sullivan · Oct 6, 2025
12. CompanyMulti-target partnership announcementBusiness Wire · Oct 6, 2025
13. CompanyAlgenBrain: reverse-engineering disease trajectories with CRISPR and AIBiopharma Dealmakers, Nature Portfolio · Mar 2024
14. CompanyAlgen Bio website: home, about us, technology and news pagesalgenbio.com · Sep 22, 2026
15. InvestorLifespan Vision Ventures statement on its portfolio companyPR Newswire, via Macau Business · Oct 9, 2025
16. YC dataAlgen Biotechnologies entry, Winter 2020 batchY Combinator directory